We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Factors Associated With Treatment Response to Etanercept in Juvenile Idiopathic Arthritis.
- Authors
Otten, Marieke H.; Prince, Femke H. M.; Armbrust, Wineke; ten Cate, Rebecca; Hoppenreijs, Esther P. A. H.; Twilt, Marinka; Koopman-Keemink, Yvonne; Gorter, Simone L.; Dolman, Koert M.; Swart, Joost F.; van den Berg, J. Merlijn; Wulffraat, Nico M.; van Rossum, Marion A. J.; van Suijlekom-Smit, Lisette W. A.
- Abstract
The article presents a study on the factors associated with treatment response to the tumor necrosis factor (TNF) a antagonist etanercept in juvenile idiopathic arthritis (JIA). The researchers chose all JIA patients in whom etanercept was initiated as the first biologic treatment and who could have had no less than 15 months of follow-up. They analyzed several potential baseline factors for treatment response including disease duration, antinuclear antibody positivity and age. They found that a third of the JIA patients achieved an excellent response 15 months after initiation of etanercept.
- Subjects
TUMOR necrosis factors; JUVENILE idiopathic arthritis; RHEUMATISM in children; ETANERCEPT; ANTIRHEUMATIC agents; DISEASE duration; AGE; THERAPEUTICS
- Publication
JAMA: Journal of the American Medical Association, 2011, Vol 306, Issue 21, p2340
- ISSN
0098-7484
- Publication type
Article
- DOI
10.1001/jama.2011.1671